Clinical Features and T‐Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The <scp>ISAC</scp> ‐ <scp>TFR</scp> Study
T-cell immunity in CML patients who have achieved a deep molecular response (DMR) may closely approximate that observed in healthy individuals.
Authors
- Iwao Nozawa
- Yemima Budirahardja (ORCID: https://orcid.org/0000-0003-2078-8555)
- Shinya Kimura (ORCID: https://orcid.org/0000-0003-1717-6208)
- Yukio Nakamura
- Hiroshi Ureshino (ORCID: https://orcid.org/0000-0002-5034-3699)
- Kazuharu Kamachi (ORCID: https://orcid.org/0000-0002-7346-4864)
- Keisuke Kidoguchi (ORCID: https://orcid.org/0000-0003-0712-0083)
Institutions
- Saga University (JP)
- Genesis Research Institute (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1002/cam4.71142
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Takeda Science Foundation
- Friends of Leukemia Research Fund
- Japan Society for the Promotion of Science